Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals Overview
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer.
The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.
In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
#Partners #Investment
Dec 5, 2023
finance.yahoo.com
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
#Public Trading
Nov 13, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
#Investment #Partners
Oct 9, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
#Customers #Investment
Sep 19, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
#Partners #Investment
Dec 5, 2023
finance.yahoo.com
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
#Public Trading
Nov 13, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
#Investment #Partners
Oct 9, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
#Customers #Investment
Sep 19, 2023
finance.yahoo.com
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
#Investment
View other companies you might be interested in
Eloxx Pharmaceuticals Team
No Data, yet.
Sorry, no content found under this section.
View other companies you might be interested in
Connect with
What is the reason for connecting? *
Your company *
Company website (recommended)
Please enter a valid website
Your organization type *
Please enter a valid organization type
Your position *
Add invitation message
0/300
Sending invitation...
Invitation sent
You will be able to start a conversation once [Name] accepts it.